Cabaletta Bio (MEX:CABA) Research & Development: MXN2,764.51 Mil (TTM As of Mar. 2026)


MEX:CABA Cabaletta Bio Inc MEX:CABA
14 GF Score
Price MXN54.50
! 1 Warning Sign
View Full Analysis

What is Cabaletta Bio Research & Development?

Cabaletta Bio MEX:CABA 14 Research & Development is MXN2,764.51 Mil as of Mar. 2026. GuruFocus rates MEX:CABA with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Cabaletta Bio's Research & Development for the three months ended in Mar. 2026 was MXN673.58 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was MXN2,764.51 Mil.

Cabaletta Bio  (MEX:CABA) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Cabaletta Bio Research & Development Related Terms

Cabaletta Bio Research & Development Historical Data

* Premium members only.

The historical data trend for Cabaletta Bio's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cabaletta Bio Research & Development Chart

Cabaletta Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only 666.58 766.19 940.78 2,027.24 2,568.95

Cabaletta Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 593.66 708.69 730.54 651.70 673.58
MEX:CABA
14GF Score
Cabaletta Bio Inc MEX:CABA
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cabaletta Bio Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN2,764.51 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of MXN2,764.51 Mil mean?
Cabaletta Bio (MEX:CABA) has a Research & Development of MXN2,764.51 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Cabaletta Bio and its competitors.
Is Cabaletta Bio's Research & Development too high?
Cabaletta Bio's current Research & Development is MXN2,764.51 Mil. Overall, Cabaletta Bio has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Research & Development compare to RZLT and CCCC?
Cabaletta Bio's Research & Development of MXN2,764.51 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Cabaletta Bio and its competitors. Cabaletta Bio's current Research & Development is MXN2,764.51 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (MEX:CABA) has a current Research & Development of MXN2,764.51 Mil. The current Research & Development is MXN2,764.51 Mil. Cabaletta Bio's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Cabaletta Bio (MEX:CABA), the current Research & Development is MXN2,764.51 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cabaletta Bio Business Description

Other Exchanges CABA:USA
Address 2929 Arch Street, Suite 600, Philadelphia, PA, USA, 19104
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
14GF Score

Get the complete analysis for MEX:CABA

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN54.50
Price